🇺🇸 FDA
Pipeline program

EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

C4551002

Phase 3 small_molecule active

Quick answer

EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144 for Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials